Disease Safety, Immunogenicity, and Efficacy of Recombinant Herpes Zoster Vaccine (RZV or Shingrix) in Autoimmune Rheumatic Diseases: Launching a Randomized Phase 4 Study.

已完结 15 由猪猪侠发布于 2026/8/5 7:31:16

DOI:10.1097/RHU.0000000000002216
作者：Leonard V K Kupa,Ana Cristina Medeiros-Ribeiro,Nádia E Aikawa,Sandra G Pasoto,Eduardo F Borba,Ana Paula L Assad,?Carla G S Saad,?Emily F N Yuki,?Luciana P C Seguro,?Danieli Andrade,?Samuel K Shi
文献类型：期刊论文
补充材料：只需要正文

其它数据库

Abstract：Background: Patients with autoimmune rheumatic diseases (ARDs) are at an increased risk for herpes zoster (HZ). Vaccination is recommended for this population.Objective: The aim of this stud

应助信息

20小时前

yangxiang

f33af5fe908111f1ba4034735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2026/8/5 7:31:16 未找到该文献，机器人已退出，请等待人工下载

2026/8/5 7:31:16 Book学术AI机器人收到请求，开始寻找文献

2026/8/5 7:31:16 已向机器人发送请求

1天前

猪猪侠发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Recombinant herpes zoster vaccine in patients with autoimmune rheumatic diseases in Brazil: a double-blind, randomised, placebo-controlled, phase 4, non-inferiority study